Pharma Intelligence on HIV Disease Coverage Forecast


The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Read the full report: 

Market Snapshot

B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
Rapid uptake of TAF-based regimens in the US will protect Gilead’s revenues following TDF patent expiry.
B/F/TAF’s potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.

Read the full report:

About Author

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow by Email